How Effective Is Humira for Psoriasis?
Humira (adalimumab) treats moderate to severe plaque psoriasis in adults who need systemic therapy or phototherapy. In clinical trials, 71-80% of patients achieved at least 75% skin clearance (PASI 75) after 12 weeks, compared to 9-19% on placebo. About 40-50% reached near-complete clearance (PASI 90), and 20-30% achieved total clearance (PASI 100).[1][2]
What Do Key Clinical Trials Show?
Pivotal phase 3 trials (REVEAL and CHAMPION) enrolled over 1,700 patients. In REVEAL, 71% on Humira hit PASI 75 at week 12 versus 7% on placebo; this rose to 80% at week 16. CHAMPION showed 81% PASI 75 on Humira versus 19% on methotrexate alone. Long-term data: 57% maintained PASI 75 at week 260 with continuous dosing. Physician global assessment rated skin mostly or completely clear in 63-75% of responders.[1][3]
How Long Until It Works and How Long Does It Last?
Improvement starts by week 4 (about 50% PASI 75), peaks at 12-16 weeks. Every-other-week dosing sustains response; up to 80% retain PASI 75 after 3 years. If stopped, psoriasis often recurs within months, but restarting restores efficacy in most.[2][4]
Who Responds Best and Who Doesn't?
Best in moderate-severe plaque psoriasis (PASI >12 or BSA >10%). Less effective in pustular, erythrodermic, or guttate types. Responders are often biologic-naive; prior failures (e.g., to etanercept) reduce odds by 20-30%. Obesity lowers response rates by 10-15%; weight-based dosing isn't used. Age, sex, and baseline severity have minimal impact.[1][5]
How Does Humira Compare to Other Biologics?
Versus TNF blockers like etanercept: Humira superior (80% vs 47% PASI 75 at 12 weeks). Vs IL-17s like secukinumab: similar PASI 75 (80-85%), but IL-17s edge out on PASI 90 (60% vs 40%) and nail/skin speed. Vs IL-23s like guselkumab: comparable short-term, but IL-23s better long-term (70% PASI 90 at 1 year). Head-to-heads favor Humira over methotrexate.[3][6]
| Drug | PASI 75 at 12 Weeks | PASI 90 at 12 Weeks |
|------|----------------------|----------------------|
| Humira | 71-81% | 40-50% |
| Secukinumab | 77-82% | 55-60% |
| Guselkumab | 73-84% | 50-65% |
| Etanercept | 47-49% | 20-25% |
Common Side Effects and Safety Concerns
Infections (51%, mostly upper respiratory) top the list; serious ones in 4%. Injection-site reactions in 14%. Risks include TB reactivation (screen first), heart failure worsening, liver issues, and rare lymphoma. No increased psoriasis-specific cancer risk. Dropout rate ~10% due to adverse events.[2][4]
Real-World Effectiveness
Trials translate well: 70-75% PASI 75 at 6 months in registries like BADBIR, though 20-30% lose response yearly (anti-drug antibodies in 15-20%). Cost and access limit use; biosimilars now match efficacy at lower price.[5][7]
[1]: FDA Label for Humira (adalimumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125057s400lbl.pdf
[2]: Gordon KB et al. N Engl J Med 2006 (REVEAL trial).
[3]: Reich K et al. Lancet 2011 (CHAMPION trial).
[4]: Papp KA et al. J Am Acad Dermatol 2013 (long-term).
[5]: BADBIR registry data. Br J Dermatol 2020.
[6]: Network meta-analysis, Blauvelt A et al. Br J Dermatol 2017.
[7]: Griffiths CEM et al. Lancet 2021 (real-world).